FDA Gives Accelerated Approval to Eisai, Biogen Alzheimer’s Drug
- January 13, 2023
The Food and Drug Administration (FDA) approved January 6 under the agency’s accelerated approval pathway Eisai Co. and Biogen Inc.’s drug lecanemab-irmb, a monoclonal antibody with the brand name Leqembi™, for treating Alzheimer’s disease.
ARTICLE TAGS
You must be logged in to access this content.